CLAIM CARD
Within the immune inflammation outcome class, a substantive tension exists between Shi 2026 and Pourkarim 2025. Shi 2026 reported mixed positive findings with multiple significant p-values across inflammatory endpoints in HFpEF, whereas Pourkarim 2025 yielded a null overall effect direction in the sepsis context despite individual p-values reaching significance. This disagreement carries a severity rating of 4 in the cross-study disagreement map, reflecting a meaningful difference in outcome patterns. The divergence may partly reflect the distinct clinical contexts — chronic low-grade inflammation in HFpEF versus acute hyperinflammation in sepsis — rather than an inherent contradiction in colchicine's anti-inflammatory mechanism. However, this context-dependency underscores that the inflammatory outcome evidence remains insufficient to establish a uniform anti-inflammaging effect across populations.
Evidence grade: exploratory
Contradiction status: none
Publication: 873ff54a-3a1e-4c35-b4ff-b2bb5ab68649
Provenance: Derivation Web chain
Citation Support
source_1Mohammadnia 2025source_2Li 2025source_3Ammirati 2026source_4Pascart 2026source_5Broekhoven 2022